Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.

doi:10.1016/j.lungcan.2024.108051

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.

Lung cancer (Amsterdam, Netherlands) - 1 Jan 2025

Urtecho S Berenice, Provenzano Leonardo, Spagnoletti Andrea, Bottiglieri Achille, Pircher Chiara, Massa Giacomo, Sposetti Caterina, Proto Claudia, Brambilla Marta, Occhipinti Mario, Mazzeo Laura, Beninato Teresa, Leporati Rita, Giani Claudia, Cavalli Chiara, Serino Roberta, Prina Marco Meazza, Bassetti Anna, Nasca Vincenzo, di Mauro Rosa Maria, Abate Alice, Manglaviti Sara, Dumitrascu Andra Diana, Liberti Giorgia Di, Cassano Teresa Serra, Ganzinelli Monica, Wu Sulin, Garassino Marina Chiara, de Braud Filippo G M, Russo Giuseppe Lo, Prelaj Arsela

Abstract excerpt

INTRODUCTION: KRAS mutation the most common molecular alteration in advanced non-small cell lung cancer (NSCLC) and is associated with an unfavourable prognosis, largely due to the lack of targeted therapeutic options for the majority of the KRAS mutated isoforms. The landscape of NSCLC treatment has expanded with the introduction of immune checkpoint inhibitors (ICIs). Nonetheless, data regarding the efficacy of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Aged, 80 and over

Share to Carcinoma, Non-Small-Cell Lung

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Lung Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed

Identifiers

PMID: 39740426
DOI: 10.1016/j.lungcan.2024.108051

Genes

KRAS
STK11
TP53

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 17 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review.PMID 39740426Read ↗

Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.Semantic proximity Read ↗

Clinical outcomes of KRAS G12C versus non-G12C mutant NSCLC treated with immunotherapy: a multicentre real-world study.Semantic proximity Read ↗

[Gene mutation profiles and clinicopathological features of patients with non-small cell lung cancer harboring KRAS G12C mutation: a single-center retrospective study].Semantic proximity Read ↗

Molecular and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer Harboring KRAS G12V Mutations.Semantic proximity Read ↗

Literature review of advances and challenges in KRAS G12C mutant non-small cell lung cancerSemantic proximity Read ↗

Clinicopathological Characteristics and Prognostic Impact of KRAS Mutations in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations.Semantic proximity Read ↗

The KRAS G12C mutation in NSCLC: from target to resistanceSemantic proximity Read ↗

Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.Semantic proximity Read ↗

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.Semantic proximity Read ↗

Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.Semantic proximity Read ↗

Brief Report: Not Created Equal: Survival Differences by KRAS Mutation Subtype in NSCLC Treated With ImmunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.